OkaiDx™ Colorectal Cancer Detection Blood Test

Booth No: M709

Characteristic

OkaiDx™ Colorectal Cancer Blood Test is based on non-invasive cfDNA methylation analysis. With a simple blood draw, it detects colorectal cancer-related molecular signals and provides molecular-level adjunct testing information. Clinical validation data show an overall sensitivity of 90.62% (Stage I detection capability >85%), overall specificity of 98.11%, and overall accuracy of 95.29%. Compared with the conventional CEA tumor marker, which may be affected by inflammation, benign diseases, or other physiological conditions, OkaiDx™ analyzes cancer-related DNA methylation signals to provide more specific molecular adjunct testing information.
This test is suitable for adoption by healthcare institutions, health screening centers, and channel partners. It can be applied to early molecular adjunct detection of cancer, high-risk population follow-up, postoperative MRD monitoring, and recurrence risk management. The test is performed in a U.S. CLIA/CAP dual-certified clinical laboratory. The related technology has been patented in Taiwan, China, Europe, Japan, Malaysia, and Australia. EG BioMed can also help partners establish differentiated molecular testing services aligned with international quality standards.